Kamada (NASDAQ:KMDA) and Neurogene (NASDAQ:NGNE) Live Analysis

Kamada ( NASDAQ:KMDA – Get Your Free Report ) and Neurogene ( NASDAQ:NGNE – Get Your Free Report ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.

Analyst recommendations

This is a summary of current ratings and price targets for Kamada and Neurogene, as reported by MarketBeat.

Kamada currently has a consensus target price of $14.50, indicating a potential upside of 176.72%. Neurogene has a consensus target price of $51.00, indicating a potential upside of 27.69%. Given Kamada’s higher possible upside, analysts plainly believe Kamada is more favorable than Neurogene.

return

This table compares Kamada and Neurogene’s net margins, return on equity and return on assets.

Rating and Earnings

This table compares Kamada and Neurogene’s revenue, earnings per share (EPS), and valuation.

Kamada has higher revenue and earnings than Neurogene.

Institutional and privileged ownership

20.4% of Kamada shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 9.9% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and big money managers believe a company will outperform the market over the long term.

Volatility and risk

Kamada has a beta of 1.07, meaning its share price is 7% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.49, meaning its share price is 49% more volatile than the S&P 500. more volatile than the S&P 500.

Summary

Kamada beats Neurogene on 7 of the 13 factors compared between the two stocks.

About Kamada

(Get a free report)

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for the treatment of rabies prophylaxis; CYTOGAM for cytomegalovirus disease prophylaxis in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post-exposure prophylaxis of chicken pox; WINRHO SDF for immune thrombocytopenic purpura and suppression of Rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence, liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of the newborn; KAMRHO (D) IV for immune thermobocytoponic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snakebite. The company also distributes imported drug products in Israel, including BRAMITOB for the management of chronic lung infections; FOSTER for treating asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEC device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus and mild-moderate juvenile dermatomyositis; IVIG for conditions related to immunodeficiency; VARITEC for chicken pox and herpes zoster; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; SODIUM HEPARIN INJECTION for thromboembolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia B. Additionally, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannose; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for different types of cancer. The company was founded in 1990 and is headquartered in Rehovot, Israel.

About Neurogenes

(Get a free report)

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The Company’s product candidates include NGN-401, which is packaged into an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate, which is in Phase 1/2 clinical trial for the treatment of CLN5 Batten disease. Has a license agreement with University of North Carolina, University of Edinburgh, Virovek, Inc. and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Get news and reviews for Kamada Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kamada and related companies with MarketBeat.com’s FREE daily email newsletter.